Publications by authors named "Tiffany Foo"

Introduction: The outcome of patients with metastatic colorectal cancer (mCRC) has improved significantly in the last few decades. Metastatic colorectal cancer is a highly heterogenous cancer. Beyond second line chemotherapy, treatment decisions are often based on molecular testing.

View Article and Find Full Text PDF

Serous cystadenoma is a rare lesion in the para-testicular tissue, with even rarer reports of this entity occurring in the scrotum post-orchidopexy. We present such an occurrence, adding support for its existence as a distinct entity.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with metastatic pancreatic cancer have a really low survival rate of only 3-5% over 5 years because there aren't many effective treatments available.
  • Only a small number of patients with a specific gene mutation see better outcomes with a drug called olaparib.
  • New treatment methods are being explored, focusing on improving the tumor environment and using advanced DNA testing to personalize therapies for patients.
View Article and Find Full Text PDF
Article Synopsis
  • Gastrointestinal stromal tumours (GISTs) are the most common type of mesenchymal tumours in the gastrointestinal tract, and the advent of tyrosine kinase inhibitors (TKIs) has significantly improved treatment options for advanced cases.
  • Imatinib was the first TKI approved for advanced GIST, setting a new standard of care, and now there are five approved targeted therapies available, including sunitinib and regorafenib, following key clinical trials like GRID and INVICTUS.
  • The Australasian Gastrointestinal Trials Group (AGITG) highlights the importance of molecular testing to guide therapy based on specific molecular targets, as well as future directions for treating advanced GISTs.
View Article and Find Full Text PDF

FH Tumour Predisposition Syndrome, also known as Hereditary Leiomyomatosis and renal cell cancer (HLRCC), or Reed Syndrome, is an autosomal dominant condition clinically characterized by multiple cutaneous leiomyomas, multiple early-onset uterine leiomyomas and early-onset renal cell cancer. Here we report a young female with FH Tumour Predisposition Syndrome with no clinical features except early-onset uterine leiomyomas. Whilst there is a significant history of uterine leiomyomas in her family, there is no history of cutaneous leiomyomas or renal cell cancer (RCC).

View Article and Find Full Text PDF

Poly (ADP-ribose) polymerase (PARP) inhibitors have transformed the management of recurrent ovarian cancer in patients with BRCA-mutations and beyond. Olaparib was the first PARP inhibitor to gain approval as maintenance therapy for patients with newly diagnosed, advanced BRCA-mutated ovarian cancer establishing a new standard of care. At the end of 2020, as a result of the SOLO1, PRIMA, and PAOLA-1 phase III trials, we are now in an era where three maintenance PARP inhibitor strategies have FDA and European Medicines Agency approval in the first-line setting.

View Article and Find Full Text PDF

Despite the increasing incidence of metastatic melanoma in the older population, there are relatively limited data for those older than 75 years of age. Elderly patients are often under-represented in clinical trials. In addition, elderly patients in trials often have a lower Eastern Cooperative Oncology Group score and fewer comorbidities and may thus not truly reflect the realities of day-to-day clinical practice.

View Article and Find Full Text PDF

Despite the increasing incidence of metastatic melanoma in the older population, there is relatively limited specific data surrounding the use of immunotherapy for the treatment of advanced melanoma for patients above the age of 65 years. To date, there has not been a prospective trial done to evaluate the safety and efficacy of using immunotherapy to treat older patients with advanced melanoma. Older patients are often under-represented in clinical trials.

View Article and Find Full Text PDF

A 57-year old man presented with a 3.6 cm submucosal rectal cystic mass detected on colonoscopy and MRI. The lesion was deroofed, with rectal cyst fluid and cyst wall received for examination.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessiongld46mpc210b0e5c2k0uqs69jhtqn973): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once